# Phase II Trial Of ZK-EPO (ZK 219477) (Sagopilone) In Metastatic Melanoma

> **NCT00598507** · PHASE2 · COMPLETED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 35 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** ZK-EPO

## Key facts

- **NCT ID:** NCT00598507
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-05
- **Primary completion:** 2013-01
- **Final completion:** 2013-01
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2013-12-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00598507

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00598507, "Phase II Trial Of ZK-EPO (ZK 219477) (Sagopilone) In Metastatic Melanoma". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT00598507. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*